$60.50
▼ -5.4% Today
as of Sep 4, 16:54 ET
Last 30 days
Recent Press Releases & News
lean bull
▲ 4
● 21
▼ 0
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough
MRK, RPRX Stocks Hit 52-Week Highs – What Drove Today’s Gains?
Overview
52-week range
$34
$64
87% of range
Avg surprise (last 3)
+5.8%
Avg reaction (last 2)
+0.8%
100% positive
Latest IV / EM
34%
EM ±5.3% · $65 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.04 | — | — | — | — | financials |
| Wed May 6, 2026 | Mar/2026 | $1.30 | $1.22 | +6.6% | +22.6% | +0.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.67 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $1.14 | $1.10 | +3.6% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $1.06 | $0.99 | +7.1% | — | +1.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $1.21 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.23 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.01 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.16 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.50 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $0.76 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $674M | $631M | — | $609M | $579M | $568M | — | $565M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $133M | $563M | — | $427M | $210M | $534M | — | $735M |
| Net income | $18M | $295M | — | $288M | $32M | $239M | — | $544M |
| EPS (diluted) | $0.04 | $0.67 | — | $0.67 | $0.07 | $0.55 | — | $1.21 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $812M | $586M | $619M | $939M | $632M | $1.09B | $929M | $950M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $1.76B | $1.43B | $1.53B | $1.85B | $1.52B | $1.84B | $1.80B | $1.79B |
| Total assets | $19.82B | $19.82B | $19.62B | $19.35B | $18.32B | $17.61B | $18.22B | $18.04B |
| Long-term debt | $8.58B | $8.58B | $8.57B | $8.57B | $7.00B | $6.62B | $6.61B | $6.61B |
| Total liabilities | $10.03B | $9.88B | $9.91B | $9.73B | $8.82B | $7.82B | $7.88B | $7.78B |
| Total equity | $9.79B | $9.94B | $9.71B | $9.62B | $9.49B | $9.78B | $10.34B | $10.26B |